Role of the endocannabinoid system in the neurobiology of suicide

The Neurobiological Basis of Suicide

Volumn , Issue , 2012, Pages 87-111

  Yaragudri Vinod, K ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85048385076     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12215     Document Type: Chapter

References (151)

1. Alvarez-Jaimes, L., Polis, I., Parsons, L.H. 2009. Regional influence of cannabinoid CB1 receptors in the regulation of ethanol self-administration by Wistar rats. Neuropsychopharmacol. J. 2:77-85.
2. Arango, V., Underwood, M.D., Mann, J.J. 2002. Serotonin brain circuits involved in major depression and suicide. Prog. Brain Res. 136:443-453.
3. Askenazy, F.L., Sorci, K., Benoit, M., Lestideau, K., Myquel, M., Lecrubier, Y. 2003. Anxiety and impulsivity levels identify relevant subtypes in adolescents with at-risk behavior. J. Affect. Disord. 74:219-227.
4. Aso, E., Renoir, T., Mengod, G. et al. 2009. Lack of CB1 receptor activity impairs serotonergic negative feedback. J. Neurochem. 109:935-944.
5. Bambico, F.R., Cassano, T., Dominguez-Lopez, S. et al. 2010a. Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology 35:2083-2100.
6. Bambico, F.R., Nguyen, N.T., Katz, N., Gobbi, G. 2010b. Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and mono-aminergic neurotransmission. Neurobiol. Dis. 37:641-655.
7. Barna, I., Zelena, D., Arszovszki, A.C., Ledent, C. 2004. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: In vivo and in vitro studies in CB1 receptor knockout mice. Life Sci. 75:2959-2970.
8. Barrero, F.J., Ampuero, I., Morales, B. et al. 2005. Depression in Parkinson’s disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J. 5:135-141.
9. Basavarajappa, B.S., Cooper, T.B., Hungund, B.L. 1998. Chronic ethanol administration down-regulates cannabinoid receptors in mouse brain synaptic plasma membrane. Brain Res. 79:212-218.
10. Basavarajappa, B.S., Yalamanchili, R., Cravatt, B.F., Cooper, T.B., Hungund, B.L. 2006. Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice. Neuropharmacology 50:834-844.
11. Bechara, A., Van Der Linden, M. 2005. Decision-making and impulse control after frontal lobe injuries. Curr. Opin. Neurol. 18:734-739.
12. Berridge, K.C., Robinson, T.E. 2003. Parsing reward. Trends Neurosci. 26:507-513.
13. Beyer, C.E., Dwyer, J.M., Piesla, M.J. et al. 2010. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol. Dis. 39:148-155.
14. Blankman, J.L., Simon, G.M., Cravatt, B.F. 2007. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14:1347-1356.
15. Blednov, Y., Cravatt, B.F., Boehm II, S.L., Walker, D., Harris, R.A. 2007. Role of endocan-nabinoids in alcohol consumption and intoxication: Studies of mice lacking fatty acid amide hydrolase. Neuropsychopharmacology 32:1570-1582.
16. Cabral, G.A., Griffin-Thomas, L. 2009. Emerging role of the cannabinoid receptor CB2 in immune regulation: Therapeutic prospects for neuroinflammation. Exp. Rev. Mol. Med. 11:e3.
17. Caspi, A., Sugden, K., Moffitt, T.E. et al. 2003. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 301:386-389.
18. Chiang, K.P., Gerber, A.L., Sipe, J.C., Cravatt, B.F. 2004. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: Evidence for a link between defects in the endocannabinoid system and problem drug use. Hum. Mol. Genet. 13:2113-2119.
19. Christensen, R., Kristensen, P.K., Bartels, E.M., Bliddal, H., Astrup, A. 2007. Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet 370:1706-1713.
20. Colombo, G., Agabio, R., Fa, M. et al. 1998. Reduction of voluntary ethanol intake in etha-nol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol Alcoholism 33:126-130.
21. Colombo, G., Serra, S., Vacca, G., Gessa, G.L., Carai, M.A. 2004a. Suppression by baclofen of the stimulation of alcohol intake induced by morphine and WIN 55,212-2 in alcohol-preferring rats. Eur. J. Pharmacol. 492:189-193.
22. Colombo, G., Vacca, G., Serra, S., Carai, M.A.M., Gessa, G.L. 2004b. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol’s motivational proper-ties in alcohol-preferring rats. Eur. J. Pharmacol. 498:119-123.
23. Day, T.A., Rakhshan, F., Deutsch, D.G., Barker, E.L. 2001. Role of fatty acid amide hydro-lase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol. 59:1369-1375.
24. Dean, B., Sundram, S., Bradbury, R., Scarr, E., Copolov, D. 2001. Studies on [3H]CP-55940 binding in the human central nervous system: Regional specific changes in density of CB-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9-15.
25. Degenhardt, L., Hall, W., Lynskey, M. 2003. Exploring the association between cannabis use and depression. Addiction 98:1493-1404.
26. Deutsch, D.G., Glaser, S.T., Howell, J.M. et al. 2001. The cellular uptake of anan-damide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem. 276:6967-6973.
27. Devane, W.A., Hanus, L., Breuer, A. et al. 1992. Isolation and structure of a brain constituent that binds to the CB receptor. Science 258:1946-1949.
28. Di Marzo, V. 1998. Endocannabinoids: Endogenous cannabinoid receptor ligands with neuro-modulatory action. Trends Neurosci. 21:521-518.
29. Di Marzo, V., De Petrocellis, L., Bisogno, T., Melck, D. 1999. Metabolism of anandamide and 2-arachidonoylglycerol: An historical overview and some recent developments. Lipids 34:S319-S325.
30. Di Marzo, V., Fontana, A., Cadas, H. et al. 1994. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691.
31. Drevets, W.C. 2000. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog. Brain Res. 126:413-431.
32. Drevets, W.C., Bogers, W., Raichle, M.E. 2002. Functional anatomical correlates of antide-pressant drug treatment assessed using PET measures of regional glucose metabolism. Eur. Neuropsychopharmacol. 12:27-44.
33. Dwivedi, Y., Conley, R.R., Roberts, R.C., Tamminga, C.A., Pandey, G.N. 2002. [3H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victims. Am. J. Psychiatry 159:66-73.
34. Eggan, S.M., Stoyak, S.R., Verrico, C.D., Lewis, D.A. 2010. Cannabinoid CB1 receptor immu-noreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology 35:2060-2071.
35. Eisch, A.J., Bolanos, C.A., de Wit, J. et al. 2003. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: A role in depression. Biol. Psychiatry 54:994-905.
36. Emrich, H.M., Leweke, F.M., Schneider, U. 1997. Towards a cannabinoid hypothesis of schizophrenia: Cognitive impairments due to dysregulation of the endogenous cannabi-noid system. Pharmacol. Biochem. Behav. 56:803-807.
37. Fava, M., Kendler, K.S. 2000. Major depressive disorder. Neuron 8:335-341.
38. FDA briefing document. 2007. Briefing Information for FDA Advisory Committee Meeting on ZIMULTI® (Rimonabant), May 10, 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-01-sponsor-backgrounder.pdf
39. Fride, E., Sanudo-Pena, C. 2002. Cannabinoids and endocannabinoids: Behavioral and devel-opmental aspects. In The Biology of Marijuana. E. Onaivi, Ed., Harwood Academic, Reading, PA.
40. Friedman, A.S., Terras, A., Zhu, W., McCallum, J. 2004. Depression, negative self-image, and suicidal attempts as effects of substance use and substance dependence. J. Addict. Dis. 23:55-71.
41. Gallate, J.E., Saharov, T., Mallet, P.E., McGregor, I.S. 1999. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur. J. Pharmacol. 370:233-240.
42. Garcia-Gutierrez, M.S., Perez-Ortiz, J.M., Gutierrez-Adan, A., Manzanares, J. 2010. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) recep-tors. Br. J. Pharmacol. 160:1773-1784.
43. George, D.T., Herion, D.W., Jones, C.L. et al. 2010. Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology 208:37-44.
44. Giuffrida, A., Leweke, F.M., Gerth, C.W. et al. 2004. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108-2114.
45. Gobbi, G., Bambico, F.R., Mangieri, R. et al. 2005. Antidepressant-like activity and modula-tion of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. USA 102:18620-18625.
46. Gonzalez, S., Valenti, M., de Miguel, R. et al. 2004. Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. Br. J. Pharmacol. 143:455-464.
47. Griebel, G., Stemmelin, J., Scatton, B. 2005. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57:261-267.
48. Haller, J., Varga, B., Ledent, C., Barna, I., Freund, T.F. 2004. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur. J. Neurosci. 19:1906-1912.
49. Hansson, A.C., Bermudez-Silva, F.J., Malinen, H. et al 2007. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology 32:117-126.
50. Heimer, L., Van Hoesen, G.W. 2006. The limbic lobe and its output channels: Implications for emotional functions and adaptive behavior. Neurosci. Biobehav. Rev. 30:126-147.
51. Hill, M.N., Gorzalka, B.B. 2005. Pharmacological enhancement of cannabinoid CB1 recep-tor activity elicits an antidepressant-like response in the rat forced swim test. Eur. Neuropsychopharmacol. 15:593-599.
52. Hill, M.N., Ho, W.S., Hillard, C.J., Gorzalka, B.B. 2008. Differential effects of the antide-pressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. J. Neural. Trans. 115:1673-1679.
53. Hill, M.N., Patel, S., Carrier, E.J. et al. 2005. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30:508-515.
54. Hohmann, A.G., Suplita, R.L., Bolton, N.M. et al. 2005. An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108-1112.
55. Howlett, A.C. 2002. The cannabinoid receptors. Prost. Lipid Mediat. 68-69:619-631.
56. Huettel, S.A., Stowe, C.J., Gordon, E.M., Warner, B.T., Platt, M.L. 2006. Neural signatures of economic preferences for risk and ambiguity. Neuron 49:765-775.
57. Hungund, B.L., Szakall, I., Adam, A. et al. 2003. Cannabinoid CB1 receptor-knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J. Neurochem. 84:698-604.
58. Hungund, B.L., Vinod, K.Y., Kassir, S.A. et al. 2004. Upregulation of CB1 receptors and ago-nist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide vic-tims. Mol. Psychiatry 9:184-190.
59. Johann, M., Putzhammer, A., Eichhammer, P. et al. 2005. Association of the -141C Del variant of the dopamine D2 receptor (DRD2) with positive family history and suicidality in German alcoholics. Am. J. Med. Genet. B. Neuropsychiatry Genet. 132:46-49.
60. Juckel, G., Schlagenhauf, F., Koslowski, M. et al. 2006. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology 187:222-228.
61. Kalivas, P.W., Volkow, N.D. 2005. The neural basis of addiction: A pathology of motivation and choice. Am. J. Psychiatry 162:1403-1413.
62. Kamprath, K., Plendl, W., Marsicano, G. et al. 2009. Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling. Genes Brain Behav. 8:203-211.
63. Kenemans, J.L., Bekker, E.M., Lijffijt, M., Overtoom, C.C., Jonkman, L.M., Verbaten, M.N. 2005. Attention deficit and impulsivity: Selecting, shifting, and stopping. Int. J. Psychophysiol. 58:59-70.
64. Kessler, R.C., Borges, G., Walters, E.E. 1999. Prevalence of risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch. Gen. Psychiatry 56:617-626.
65. Koller, G., Preuss, U.W., Bottlender, M., Wenzel, K., Soyka, M. 2002. Impulsivity and aggression as predictors of suicide attempts in alcoholics. Arch. Psychiatry Clin. Neurosci. 252:155-160.
66. Koob, G.F. 1992. Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13:177-184.
67. Krawczyk, D.C. 2002. Contributions of the prefrontal cortex to the neural basis of human deci-sion making. Neurosci. Biobehav. Rev. 26:631-664.
68. Kumar, P., Waiter, G., Ahearn, T., Milders, M., Reid, I., Steele, J.D. 2008. Abnormal temporal difference reward-learning signals in major depression. Brain 131:2084-2093.
69. Ledent, C., Valverde, O., Cossu, G. et al. 1999. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404.
70. Lynskey, M.T., Glowinski, A.L., Todorov, A.A. 2004. Major depressive disorder, suicidal ide-ation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch. Gen. Psychiatry 61:1026-1032.
71. Maccioni, P., Colombo, G., Carai, M.A.M. 2010. Blockade of the cannabinoid CB1 recep-tor and alcohol dependence: Preclinical evidence and preliminary clinical data. CNS Neurol. Disord. Drug Targets 9:55-59.
72. Makhija, N.J., Sher, L. 2007. Preventing suicide in adolescents with alcohol use disorders. Int. J. Adolesc. Med. Health 19:53-59.
73. Malinen, H., Hyytia, P. 2008. Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats. Alcohol Clin. Exp. Res. 32:1976-1983.
74. Mangieri, R.A., Piomelli, D. 2007. Enhancement of endocannabinoid signaling and the phar-macotherapy of depression. Pharmacol. Res. 56:360-366.
75. Manji, H.K., Drevets, W.C., Charney, D.S. 2001. The cellular neurobiology of depression. Nat. Med. 7:541-547.
76. Mann, J.J. 2003. Neurobiology of suicidal behaviour. Nat. Rev. Neurosci. 4:819-828.
77. Mann, J.J., Waternaux, C., Haas, G.L., Malone, K.M. 1999. Toward a clinical model of sui-cidal behavior in psychiatric patients. Am. J. Psychiatry 156:181-189.
78. Manzanares, J., Corchero, J., Fuentes, J.A. 1999. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res. 839:173-179.
79. Manzanares, J., Uriguen, L., Rubio, G., Palomo, T. 2004. Role of endocannabinoid system in mental diseases. Neurotoxicol. Res. 6:213-224.
80. Martin, M., Ledent, C., Parmentier, M., Maldonado, R., Valverde, O. 2002. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159:379-387.
81. Matias, I., Bisogno, T., Di Marzo, V. 2006. Endogenous cannabinoids in the brain and periph-eral tissues: Regulation of their levels and control of food intake. Int. J. Obes. (Lond.) 30:S7-S12.
82. Mato, S., Vidal, R., Castro, E., Diaz, A., Pazos, A., Valdizan, E.M. 2010. Long-term fluox-etine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine 1A receptor-dependent mechanisms. Mol. Pharmacol. 77:424-434.
83. McDonald, J., Schleifer, L., Richards, J.B., de Wit, H. 2003. Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 28:1356-1365.
84. McEwen, B.S. 2005. Glucocorticoids, depression, and mood disorders: Structural remodeling in the brain. Metabolism 54:20-23.
85. Mechoulam, R., Ben-Shabat, S., Hanus, L. et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:83-90.
86. Mitrirattanakul, S., López-Valdés, H.E., Liang, J. et al. 2007. Bidirectional alterations of hip-pocampal cannabinoid 1 receptors and their endogenous ligands in a rat model of alco-hol withdrawal and dependence. Alcohol Clin. Exp. Res. 31:855-867.
87. Monteleone, P., Bifulco, M., Maina, G. et al. 2010. Investigation of CNR1 and FAAH endocan-nabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol. Res. 61:400-404.
88. Muntoni, A.L., Pillolla, G., Melis, M., Perra, S., Gessa, G.L., Pistis, M. 2006. Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus norad-renergic neurons. Eur. J. Neurosci. 23:2385-2394.
89. Murphy, L.L., Munoz, R.M., Adrian, B.A., Villanua, M.A. 1998. Function of cannabinoid recep-tors in the neuroendocrine regulation of hormone secretion. Neurobiol. Dis. 5:432-446.
90. Need, A.B., Davis, R.J., Alexander-Chacko, J.T. et al. 2006. The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacology 184:26-35.
91. Oliva, J.M., Uriguen, L., Perez-Rial, S., Manzanares, J. 2005. Time course of opioid and can-nabinoid gene transcription alterations induced by repeated administration with fluox-etine in rat brain. Neuropharmacology 49:618-626.
92. Oropeza, V.C., Page, M.E., Van Bockstaele, E.J. 2005. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res. 1046:45-54.
93. Ortiz, S., Oliva, J.M., Perez-Rial, S., Palomo, T., Manzanares, J. 2004. Chronic ethanol con-sumption regulates cannabinoid CB1 receptor gene expression in selected regions of rat brain. Alcohol Alcoholism 39:88-92.
94. O’Shea, M., McGregor, I.S., Mallet, P.E. 2006. Repeated cannabinoid exposure during perina-tal, adolescent or early adult ages produces similar long-lasting deficits in object recog-nition and reduced social interaction in rats. J. Psychopharmacol. 20:611-621.
95. O’Shea, M., Singh, M.E., McGregor, I.S., Mallet, P.E. 2004. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J. Psychopharmacol. 18:502-508.
96. Palkovits, M., Harvey-White, J., Liu, J. et al. 2008. Regional distribution and effects of postmor-tal delay on endocannabinoid content of the human brain. Neuroscience 152:1032-1039.
97. Patel, S., Hillard, C.J. 2008. Adaptations in endocannabinoid signaling in response to repeated homotypic stress: A novel mechanism for stress habituation. Eur. J. Neurosci. 27:2821-2829.
98. Patel, S., Rademacher, D.J., Hillard, C.J. 2003. Differential regulation of the endocannabi-noids anandamide and 2-arachidonoylglycerol within the limbic forebrain by dopamine receptor activity. J. Pharmacol. Exp. Ther. 306:880-888.
99. Patel, S., Roelke, C.T., Rademacher, D.J., Cullinan, W.E., Hillard, C.J. 2004. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145:5431-5438.
100. Pattij, T., Vanderschuren, L.J. 2008. The neuropharmacology of impulsive behaviour. Trends Pharmacol. Sci. 29:192-199.
101. Pfennig, A., Kunzel, H.E., Kern, N. et al. 2005. Hypothalamus-pituitary-adrenal system regu-lation and suicidal behavior in depression. Biol. Psychiatry 57:336-342.
102. Pistis, M. 2002. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: An in vivo microdialysis study. Brain Res. 948:155-158.
103. Ponce, G., Hoenicka, J., Rubio, G. et al. 2003. Association between cannabinoid receptor gene (CNR1) and childhood attention deficit/hyperactivity disorder in Spanish male alcoholic patients. Mol. Psychiatry 8:466-467.
104. Potash, J.B., Kane, H.S., Chiu, Y.F. et al. 2000. Attempted suicide and alcoholism in bipolar disorder: Clinical and familial relationships. Am. J. Psychiatry 157:2048-2050.
105. Preuss, U.W., Schuckit, M.A., Smith, T.L. et al. 2002. A comparison of alcohol-induced and independent depression in alcoholics with histories of suicide attempts. J. Stud. Alcohol 63:498-502.
106. Price, C., Hemmingsson, T., Lewis, G., Zammit, S., Allebeck, P. 2009. Cannabis and suicide: Longitudinal study. Br. J. Psychiatry 195:492-497.
107. Ramaekers, J.G., Kauert, G., van Ruitenbeek, P., Theunissen, E.L., Schneider, E., Moeller, M.R. 2006. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31:2296-2303.
108. Raphael, B., Wooding, S., Stevens, G., Connor, J. 2005. Comorbidity: Cannabis and complex-ity. J. Psychiatr. Pract. 11:161-176.
109. Reiach, J.S., Li, P.P., Warsh, J.J., Kish, S.J., Young, L.T. 1999. Reduced adenylyl cyclase immunolabeling and activity in postmortem temporal cortex of depressed suicide victims. Affect. Disorder 56:141-151.
110. Rich, C.L., Dhossche, D.M., Ghani, S., Isacsson, G. 1998. Suicide methods and presence of intoxicating abusable substances: Some clinical and public health implications. Ann. Clin. Psychiatry 10:169-175.
111. Richardson, H.N., Lee, S.Y., O’dDell, L.E., Koob, G.F., Rivier, C.L. 2008. Alcohol self-administration acutely stimulates the hypothalamic-pituitary-adrenal axis, but alcohol dependence leads to a dampened neuroendocrine state. Eur. J. Neurosci. 28:1641-1653.
112. Rodriguez de Fonseca, F., Carrera, M.R., Navarro, M., Koob, G.F., Weiss, F. 1997. Activation of corticotropin-releasing factor in the limbic system during CB withdrawal. Science 276:2050-2054.
113. Rodriguez-Gaztelumendi, A., Rojo, M.L., Pazos, A., Diaz, A. 2009. Altered CB receptor-sig-naling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine. J. Neurochem. 108:1423-1433.
114. Roy, A. 2000. Relation of family history of suicide to suicide attempts in alcoholics. Am. J. Psychiatry 157:2050-2051.
115. Schlaepfer, T.E., Cohen, M.X., Frick, C. et al. 2008. Deep brain stimulation to reward cir-cuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 33:368-377.
116. Schmidt, L.G., Samochowiec, J., Finckh, U. et al. 2002. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend. 65:221-224.
117. Self, D.W., Nestler, E.J. 1998. Relapse to drug-seeking: Neural and molecular mechanisms. Drug Alcohol Depend. 51:49-60.
118. Shearman, L.P., Rosko, K.M., Fleischer, R. et al. 2003. Antidepressant-like and anorec-tic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav. Pharmacol. 14:573-582.
119. Sher, L. 2006. Alcoholism and suicidal behavior: A clinical overview. Acta Psychiatr. Scand. 113:13-22.
120. Sher, L. 2007. The role of the hypothalamic-pituitary-adrenal axis dysfunction in the patho-physiology of alcohol misuse and suicidal behavior in adolescents. Int. J. Adolesc. Med. Health 19:3-9.
121. Sibille, E., Arango, V., Galfalvy, H.C. et al. 2004. Gene expression profiling of depression and suicide in human prefrontal cortex. Neuropsychopharmacology 29:351-361.
122. Simons, J.S., Gaher, R.M., Correia, C.J., Hansen, C.L., Christopher, M.S. 2005. An affec-tive-motivational model of marijuana and alcohol problems among college students. Psychol. Addict. Behav. 19:326-334.
123. Sipe, J.C., Chiang, K., Gerber, A.L., Beutler, E., Cravatt, B.F. 2002. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl Acad. Sci. USA 99:8394-8399.
124. Solinas, M., Justinova, J., Goldberg, S.R., Tanda, G.J. 2006. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rat. J. Neurochem. 98:408-419.
125. Solinas, M., Tanda, G., Justinova, Z. et al. 2007. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J. Pharmacol. Exp. Ther. 321:370-380.
126. Soyka, M., Koller, G., Schmidt, P. et al. 2008. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial. J. Clin. Psychopharmacol. 28:317-324.
127. Steiner, M.A., Marsicano, G., Nestler, E.J., Holsboer, F., Lutz, B., Wotjak, C.T. 2008a. Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 33:54-67.
128. Steiner, M.A., Wanisch, K., Monory, K. et al. 2008b. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenom. J. 8:196-208.
129. Sugiura, T., Kondo, S., Sukagawa, A. et al. 1995. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:89-97.
130. Suominen, K., Henriksson, M., Suokas, J., Isometsa, E., Ostamo, A., Lonnqvist, J. 1996. Mental disorders and comorbidity in attempted suicide. Acta Psychiatr. Scand. 94:234-240.
131. Tanda, G., Loddo, P., Di Chiara, G. 1999. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur. J. Pharmacol. 376:23-26.
132. Tremblay, L.K., Naranjo, C.A., Graham, S.J. et al. 2005. Functional neuroanatomical sub-strates of altered reward processing in major depressive disorder revealed by a dopami-nergic probe. Arch. Gen. Psychiatry 62:1228-1236.
133. Tzavara, E.T., Davis, R.J., Perry, K.W. et al. 2003. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for therapeutic actions. Br. J. Pharmacol. 138:544-553.
134. Uriguen, L., Perez-Rial, S., Ledent, C., Palomo, T., Manzanares, J. 2004. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46:966-973.
135. Van Sickle, M.D., Duncan, M., Kingsley, P.J. et al. 2005. Identification and functional charac-terization of brainstem cannabinoid CB2 receptors. Science 310:329-332.
136. Vinod, K.Y. Hungund, B.L. 2006. The role of endocannabinoid system in depression and sui-cide. Trends Pharmacol. Sci. 27:539-545.
137. Vinod, K.Y., Arango, V., Xie, S. et al. 2005. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide vic-tims. Biol. Psychiatry 57:480-486.
138. Vinod, K.Y., Hungund, B.L. 2005. Endocannabinoid lipids and mediated system: Implications for alcoholism and neuropsychiatric disorders. Life Sci. 77:1569-1583.
139. Vinod, K.Y., Kassir, S.A., Hungund, B.L., Cooper, T.B., Mann, J.J., Arango, V. 2010. Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral stria-tum of alcoholics and suicides. J. Psychiatr. Res. 44:591-597.
140. Vinod, K.Y., Maccioni, P., Garcia-Gutierrez, M.S., et al. 2012. Innate difference in the endo-cannabinoid signaling and its modulation by alcohol consumption in alcohol-preferring sP rats. Addict. Biol. 17:62-75.
141. Vinod, K.Y., Sanguino, E., Yalamanchili, R., Manzanares, J., Hungund, B.L. 2008a. Manipulation of fatty acid amide hydrolase functional activity alters sensitivity and dependence to ethanol. J. Neurochem. 104:233-243.
142. Vinod, K.Y., Yalamanchili, R., Thanos, P.K. et al. 2008b. Genetic and pharmacological manip-ulations of the CB1 receptor alter ethanol consumption and dependence in ethanol-preferring and ethanol non-preferring mice. Synapse 62:574-581.
143. Wang, L., Liu, J., Harvey-White, J., Zimmer, A., Kunos, G. 2003. Endocannabinoid signal-ing via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc. Natl. Acad. Sci. USA 100:1393-1398.
144. Wang, W., Sun, D., Pan, B. et al. 2010. Deficiency in endocannabinoid signaling in the nucleus accumbens induced by chronic unpredictable stress. Neuropsychopharmacology 35:2249-2261.
145. Wenger, T., Ledent, C., Tramu, G. 2003. The endogenous cannabinoid, anandamide, activates the hypothalamo-pituitary-adrenal axis in CB1 cannabinoid receptor knockout mice. Neuroendocrinology 78:294-300.
146. Wilson, R.I., Nicoll, R.A. 2002. Endocannabinoid signaling in the brain. Science 296:678-682.
147. Witkin, J.M., Tzavara, E.T., Davis, R.J., Li, X., Nomikos, G.G. 2005. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol. Sci. 26:609-617.
148. Zarate, J., Churruca, I., Echevarria, E. et al. 2008. Immunohistochemical localization of CB1 cannabinoid receptors in frontal cortex and related limbic areas in obese Zucker rats: Effects of chronic fluoxetine treatment. Brain Res. 1236:57-72.
149. Zavitsanou, K., Garrick, T., Huang, X.F. 2004. Selective antagonist [3H]SR141716A binding to CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 28:355-360.
150. Zimmer, A., Zimmer, A.M., Hohmann, A.G., Herkenham, M., Bonner, T.I. 1999. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl Acad. Sci. USA 96:5780-5785.
151. Zuo, L., Kranzler, H.R., Luo, X., Covault, J., Gelernter, J. 2007. CNR1 variation modulates risk for drug and alcohol dependence. Biol. Psychiatry 62:616-626.